Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q93009: Variant p.Gly392Asp

Ubiquitin carboxyl-terminal hydrolase 7
Gene: USP7
Feedback?
Variant information Variant position: help 392 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glycine (G) to Aspartate (D) at position 392 (G392D, p.Gly392Asp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to medium size and acidic (D) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In HAFOUS. Any additional useful information about the variant.


Sequence information Variant position: help 392 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1102 The length of the canonical sequence.
Location on the sequence: help QLDGDNKYDAGEHGLQEAEK G VKFLTLPPVLHLQLMRFMYD The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         QLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYD

Mouse                         QLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYD

Rat                           QLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYD

Chicken                       QLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYD

Caenorhabditis elegans        ILDDENKYDAGDHGLQRAEKGVKFVELPPILHVQLMRFQY-

Drosophila                    TLEGDNKYDAGVHGLQEASKGVIFTSFPPVLHLHLMRFQYD

Baker's yeast                 KFD-------------------------------YIVYYTD

Fission yeast                 AHE-------------------------------LLRLLLD
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1102 Ubiquitin carboxyl-terminal hydrolase 7
Domain 214 – 521 USP
Beta strand 389 – 396



Literature citations
Pathogenic variants in USP7 cause a neurodevelopmental disorder with speech delays, altered behavior, and neurologic anomalies.
Fountain M.D.; Oleson D.S.; Rech M.E.; Segebrecht L.; Hunter J.V.; McCarthy J.M.; Lupo P.J.; Holtgrewe M.; Moran R.; Rosenfeld J.A.; Isidor B.; Le Caignec C.; Saenz M.S.; Pedersen R.C.; Morgan T.M.; Pfotenhauer J.P.; Xia F.; Bi W.; Kang S.L.; Patel A.; Krantz I.D.; Raible S.E.; Smith W.; Cristian I.; Torti E.; Juusola J.; Millan F.; Wentzensen I.M.; Person R.E.; Kuery S.; Bezieau S.; Uguen K.; Ferec C.; Munnich A.; van Haelst M.; Lichtenbelt K.D.; van Gassen K.; Hagelstrom T.; Chawla A.; Perry D.L.; Taft R.J.; Jones M.; Masser-Frye D.; Dyment D.; Venkateswaran S.; Li C.; Escobar L.F.; Horn D.; Spillmann R.C.; Pena L.; Wierzba J.; Strom T.M.; Parenti I.; Kaiser F.J.; Ehmke N.; Schaaf C.P.;
Genet. Med. 21:1797-1807(2019)
Cited for: VARIANTS HAFOUS ILE-225; LYS-345; PHE-373; ASP-392; GLY-485; 576-CYS--ASN-1102 DEL; PRO-757; THR-766 AND ASN-1080; INVOLVEMENT IN HAFOUS;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.